Background:
Ipilimumab is a first-in-class T-cell potentiator that works by blocking CTLA-4, a critical negative regulator of the anti-tumor T-cell response. In response to full T-cell activation, CTLA-4 is upregulated and competes with CD28 for CD80 and CD86 binding on antigen presenting cells but with significantly higher affinity, therefore downregulatingor deactivatingthe T cells. CTLA-4, therefore, downregulates T-cell responses and antigen presenting cell function, resulting in a decreased immune response to tumor associated antigens and immune tolerance. A fully humanized IgG1 monoclonal antibody, by blocking CTLA-4, Ipilimumab removes an inhibitory signal from reducing the activity of T lymphocytes.
Intended Use:
For Estimation of Ipilimumab (YERVOY) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Ipilimumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Ipilimumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Human IgG antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Ipilimumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!
